Details der Publikation - Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers

Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers / Gerhard Opelz, Bernd Döhler

BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are widely prescribed after kidney transplantation, but evidence for an improvement in outcomes is mixed. A recent trial demonstrated a significantly lower incidence of major cardiovascular events in ACEI-treated recipients. - METHODS: Collaborative Transplant Study data on cardiovascular death during years 2 to 10 after kidney transplantation in patients with a functioning graft were analyzed according to whether ACEI/ARB or other antihypertensive therapy (excluding diuretics) was administered at year 1. - RESULTS: Of 39,251 transplants analyzed, 15,250 (38.9%) received ACEI/ARB and 24,001 (61.1%) received other antihypertensive therapy at year 1 after transplantation. The mean duration of follow-up was 5.8 years. During years 2 to 10 after transplantation, cardiovascular death occurred in 918 patients (cumulative incidence=4.7%) with a functioning graft. The rate of cardiovascular death was similar in patients who received ACEI/ARB therapy or other antihypertensive treatment overall and in subpopulations of patients who were considered by the transplant center to be at an increased cardiovascular risk, had no pretransplant risk factors, were aged 60 years and older, were treated for diabetes at year 1, or had serum creatinine of 130 μmol/L or higher at year 1. Multivariable Cox regression analysis confirmed that treatment with ACEI/ARB did not confer a beneficial effect beyond that conferred by other antihypertensive treatments on the cumulative incidence of cardiovascular death during years 2 to 10 (hazard ratio=1.1, P=0.24). - CONCLUSIONS: This large-scale retrospective analysis of prospectively collected data shows that the rate of cardiovascular death in kidney transplant recipients receiving ACEI/ARB or other antihypertensive medications is virtually identical..

Medienart:	E-Artikel

Erscheinungsjahr:	2014 Feb 15 2014
Erschienen:	2014 Feb 15

Enthalten in:	Zur Gesamtaufnahme - volume:97
Enthalten in:	Transplantation - 97(2014), 3, Seite 310-315

Sprache:	Englisch

Beteiligte Personen:	Opelz, Gerhard, 1944- [VerfasserIn] Döhler, Bernd [VerfasserIn]

Links:	Volltext [lizenzpflichtig] Volltext [lizenzpflichtig]

Themen:	Adolescent Adult Angiotensin Receptor Antagonists Angiotensin-Converting Enzyme Inhibitors Cardiovascular Diseases Female Graft Survival Humans Incidence Kidney Transplantation Male Middle Aged Postoperative Period Proportional Hazards Models Renin-Angiotensin System Retrospective Studies Risk Factors Software Time Factors Treatment Outcome Young Adult

Anmerkungen:	Gesehen am 24.09.2020

Umfang:	6

doi:	10.1097/01.TP.0000437672.78716.28

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	1733680160

Internformat


LEADER	01000caa a2200265 4500
001	1733680160
003	DE-627
005	20230426163444.0
007	cr uuu---uuuuu
008	200924s2014 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1097/01.TP.0000437672.78716.28 \|2 doi
035			\|a (DE-627)1733680160
035			\|a (DE-599)KXP1733680160
035			\|a (OCoLC)1341361608
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
100	1		\|a Opelz, Gerhard \|d 1944- \|e verfasserin \|0 (DE-588)1026480345 \|0 (DE-627)726772453 \|0 (DE-576)371826527 \|4 aut
245	1	0	\|a Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers \|c Gerhard Opelz, Bernd Döhler
264		1	\|c 2014 Feb 15
300			\|a 6
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a Gesehen am 24.09.2020
520			\|a BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are widely prescribed after kidney transplantation, but evidence for an improvement in outcomes is mixed. A recent trial demonstrated a significantly lower incidence of major cardiovascular events in ACEI-treated recipients. - METHODS: Collaborative Transplant Study data on cardiovascular death during years 2 to 10 after kidney transplantation in patients with a functioning graft were analyzed according to whether ACEI/ARB or other antihypertensive therapy (excluding diuretics) was administered at year 1. - RESULTS: Of 39,251 transplants analyzed, 15,250 (38.9%) received ACEI/ARB and 24,001 (61.1%) received other antihypertensive therapy at year 1 after transplantation. The mean duration of follow-up was 5.8 years. During years 2 to 10 after transplantation, cardiovascular death occurred in 918 patients (cumulative incidence=4.7%) with a functioning graft. The rate of cardiovascular death was similar in patients who received ACEI/ARB therapy or other antihypertensive treatment overall and in subpopulations of patients who were considered by the transplant center to be at an increased cardiovascular risk, had no pretransplant risk factors, were aged 60 years and older, were treated for diabetes at year 1, or had serum creatinine of 130 μmol/L or higher at year 1. Multivariable Cox regression analysis confirmed that treatment with ACEI/ARB did not confer a beneficial effect beyond that conferred by other antihypertensive treatments on the cumulative incidence of cardiovascular death during years 2 to 10 (hazard ratio=1.1, P=0.24). - CONCLUSIONS: This large-scale retrospective analysis of prospectively collected data shows that the rate of cardiovascular death in kidney transplant recipients receiving ACEI/ARB or other antihypertensive medications is virtually identical.
650		4	\|a Adolescent
650		4	\|a Adult
650		4	\|a Angiotensin Receptor Antagonists
650		4	\|a Angiotensin-Converting Enzyme Inhibitors
650		4	\|a Cardiovascular Diseases
650		4	\|a Female
650		4	\|a Graft Survival
650		4	\|a Humans
650		4	\|a Incidence
650		4	\|a Kidney Transplantation
650		4	\|a Male
650		4	\|a Middle Aged
650		4	\|a Postoperative Period
650		4	\|a Proportional Hazards Models
650		4	\|a Renin-Angiotensin System
650		4	\|a Retrospective Studies
650		4	\|a Risk Factors
650		4	\|a Software
650		4	\|a Time Factors
650		4	\|a Treatment Outcome
650		4	\|a Young Adult
700	1		\|a Döhler, Bernd \|e verfasserin \|0 (DE-588)1121948634 \|0 (DE-627)875040691 \|0 (DE-576)481065997 \|4 aut
773	0	8	\|i Enthalten in \|t Transplantation \|d Hagerstown, Md. : Lippincott Williams & Wilkins, 1963 \|g 97(2014), 3, Seite 310-315 \|h Online-Ressource \|w (DE-627)32529738X \|w (DE-600)2035395-9 \|w (DE-576)097188794 \|x 1534-6080 \|7 nnns
773	1	8	\|g volume:97 \|g year:2014 \|g number:3 \|g pages:310-315 \|g extent:6
856	4	0	\|u https://doi.org/10.1097/01.TP.0000437672.78716.28 \|x Verlag \|x Resolving-System \|z lizenzpflichtig \|3 Volltext
856	4	0	\|u https://pubmed.ncbi.nlm.nih.gov/24492421/ \|x Verlag \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ILN_2013
912			\|a ISIL_DE-16-250
912			\|a SYSFLAG_1
912			\|a GBV_KXP
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_121
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_187
912			\|a GBV_ILN_206
912			\|a GBV_ILN_266
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_374
912			\|a GBV_ILN_602
912			\|a GBV_ILN_647
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2018
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2869
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4346
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4753
936	u	w	\|d 97 \|j 2014 \|e 3 \|h 310-315 \|g 6
951			\|a AR
952			\|d 97 \|j 2014 \|e 3 \|h 310-315 \|g 6
980			\|2 2013 \|1 01 \|x DE-16-250 \|b 3760810683 \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j --%%-- \|y l01 \|z 24-09-20
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 00 \|s s \|a hd2014
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 01 \|s s \|0 (DE-627)1410508463 \|a wissenschaftlicher Artikel (Zeitschrift)
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 02 \|s s \|a per_2
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 03 \|s s \|a s_6
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s p \|0 (DE-627)1441826823 \|a Opelz, Gerhard
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s k \|0 (DE-627)1416466967 \|a Medizinische Fakultät Heidelberg
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|a pos_1
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s p \|0 (DE-627)1551066149 \|a Döhler, Bernd
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s k \|0 (DE-627)1416741488 \|a Institut für Immunologie und Serologie
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s s \|a pos_2

Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers / Gerhard Opelz, Bernd Döhler

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände